Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its Meeting held on Wednesday, November 12, 2025, inter-alia considered and approved the Unaudited Financial Results of the Company for the quarter and half year ended September 30, 2025. A copy of the same is enclosed along with the Limited Review Report of the Statutory Auditors thereon in terms of SEBI (LODR) Regulations, 2015.The Meeting of the Board of Directors of the Company commenced at 03:00 p.m. and concluded at 03.30 p.m.Kindly take the above information on your records.
SUPRIYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Supriya Lifescience has informed the stock exchanges that its Board of Directors, at a meeting held on November 12, 2025, approved the unaudited financial results for the quarter and half year ended September 30, 2025. The statutory auditors have also submitted their Limited Review Report on these results, as required under SEBI's listing rules. This is a routine procedural disclosure filed under Regulation 30 of SEBI LODR. No actual financial figures have been shared in this filing — investors will need to refer to the attached results document for detailed numbers.
This is a standard compliance filing with no direct impact on the stock price. The actual numbers in the attached results (revenue, profit, margins) will be the key drivers of market reaction once analysts and investors review them.